Solid Biosciences Appoints Kevin Tan, CFA, as Chief Financial Officer
CHARLESTOWN, Mass., Jan. 09, 2023 (GLOBE NEWSWIRE) — Solid Biosciences Inc. (Nasdaq:SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, today announced the appointment of Kevin Tan, CFA, a seasoned industry professional, as Chief Financial Officer.
Related news for (SLDB)
- Solid Biosciences Reports First Quarter 2025 Financial Results and Provides Business Updates
- Solid Biosciences to Present at the American Society of Gene and Cell Therapy’s 28th Annual Meeting
- Don’t Miss Out: MoBot’s Latest Stock Updates 04/21/25 12:00 PM
- Solid Biosciences to Participate at Upcoming Investor Conferences
- Solid Biosciences to Present at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference